BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim JW, Cho YB, Lee S. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021;10:670. [PMID: 33802964 DOI: 10.3390/cells10030670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu J, Zhang C, Song C. Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114516] [Reference Citation Analysis]
2 Pugh KW, Alnaed M, Brackett CM, Blagg BSJ. The biology and inhibition of glucose-regulated protein 94/gp96. Med Res Rev 2022. [PMID: 35861260 DOI: 10.1002/med.21915] [Reference Citation Analysis]
3 Kim JW, Cho YB, Lee S. Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10, 670. Cells 2021;10:1198. [PMID: 34069315 DOI: 10.3390/cells10051198] [Reference Citation Analysis]
4 Fernandez E, Ubillos L, Elgul N, Festari MF, Mazal D, Pritsch O, Alonso I, Osinaga E, Berois N. Polypeptide-GalNAc-Transferase-13 Shows Prognostic Impact in Breast Cancer. Cancers (Basel) 2021;13:5616. [PMID: 34830771 DOI: 10.3390/cancers13225616] [Reference Citation Analysis]
5 Yun S, Lee S, Lee HY, Oh HJ, Kwak Y, Lee HS. Clinicopathologic and Prognostic Association of GRP94 Expression in Colorectal Cancer with Synchronous and Metachronous Metastases. Int J Mol Sci 2021;22:7042. [PMID: 34208855 DOI: 10.3390/ijms22137042] [Reference Citation Analysis]